SCHEMBL6769992

SCHEMBL6769992

COc1cc(CNc2ccc3oc4ccc(F)cc4c3c2)cc(OC)c1

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
DHFR P00374 1/20 0.49
HIF1A Q16665 1/20 0.44
MAPT P10636 3/20 0.43
MEN1 O00255 1/20 0.43
KMT2A Q03164 1/20 0.43
CNR2 P34972 2/20 0.43
NTRK1 P04629 2/20 0.42
NTRK3 Q16288 1/20 0.42
NTRK2 Q16620 1/20 0.42
CLK1 P49759 4/20 0.42
DYRK1A Q13627 4/20 0.42
BCHE P06276 1/20 0.41
CNR1 P21554 1/20 0.41
NPC1 O15118 1/20 0.41
LMNA P02545 1/20 0.41
RAB9A P51151 1/20 0.41
L3MBTL1 Q9Y468 1/20 0.41
KDM4E B2RXH2 1/20 0.41
ALDH1A1 P00352 1/20 0.41
GAA P10253 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6491163 0.90 RAB9A (0.53) MAPTMEN1KMT2ACNR2CLK1
SCHEMBL6483468 0.89 MAPT (0.58) HIF1AMAPTMEN1KMT2ACLK1
SCHEMBL6494943 0.87 DHFR (0.51) DHFRHIF1AMAPTMEN1KMT2A
SCHEMBL6490342 0.86 HIF1A (0.51) DHFRHIF1AMAPTMEN1KMT2A
SCHEMBL6765296 0.85 DHFR (0.49) DHFRHIF1AMAPTMEN1KMT2A
SCHEMBL6482716 0.84 CLK1 (0.41) CNR2NTRK1NTRK3NTRK2CLK1
SCHEMBL6484551 0.82 USP10 (0.48) CNR2NTRK1NTRK3NTRK2BCHE
SCHEMBL6496806 0.81 MAPT (0.49) DHFRHIF1AMAPTMEN1KMT2A
SCHEMBL6768170 0.81 MEN1 (0.59) DHFRHIF1AMAPTMEN1KMT2A
SCHEMBL6493222 0.80 MAPT (0.48) MAPTMEN1KMT2ANTRK1NTRK3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6800656-B2 Tricyclic compounds and method of treating herpes virus WARNER LAMBERT COMPANY 2004-10-05 US claimed
US-20030229073-A1 Tricyclic compounds and method of treating herpes virus BOOTH RICHARD JOHN (US) 2003-12-11 US claimed
EP-1248777-A2 TRICYCLIC COMPOUNDS WITH ANTIVIRAL ACTIVITY WARNER-LAMBERT COMPANY (US) 2002-10-16 EP claimed
WO-2001051479-A2 TRICYCLIC COMPOUNDS WITH ANTIVIRAL ACTIVITY WARNER-LAMBERT COMPANY (US) 2001-07-19 WO claimed
US-6800656-B2 Tricyclic compounds and method of treating herpes virus WARNER LAMBERT COMPANY 2004-10-05 US disclosed
US-20030229073-A1 Tricyclic compounds and method of treating herpes virus BOOTH RICHARD JOHN (US) 2003-12-11 US disclosed
EP-1248777-A2 TRICYCLIC COMPOUNDS WITH ANTIVIRAL ACTIVITY WARNER-LAMBERT COMPANY (US) 2002-10-16 EP disclosed
WO-2001051479-A2 TRICYCLIC COMPOUNDS WITH ANTIVIRAL ACTIVITY WARNER-LAMBERT COMPANY (US) 2001-07-19 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030229073-A1 Tricyclic compounds and method of treating herpes virus HDAC8, ZC3HAV1, ZCCHC8 DHFR 666/4885HIF1A 3185/4885MAPT 2337/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.